Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| fibroblast | 8 studies | 20% ± 4% | |
| pericyte | 8 studies | 21% ± 4% | |
| smooth muscle cell | 7 studies | 19% ± 4% | |
| endothelial cell | 7 studies | 23% ± 5% | |
| ciliated cell | 6 studies | 28% ± 11% | |
| endothelial cell of vascular tree | 6 studies | 20% ± 2% | |
| endothelial cell of artery | 5 studies | 18% ± 3% | |
| mast cell | 4 studies | 23% ± 6% | |
| myeloid cell | 4 studies | 23% ± 3% | |
| classical monocyte | 3 studies | 23% ± 3% | |
| non-classical monocyte | 3 studies | 27% ± 5% | |
| B cell | 3 studies | 21% ± 2% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 18% ± 2% | |
| epithelial cell | 3 studies | 29% ± 9% | |
| macrophage | 3 studies | 22% ± 5% | |
| endothelial cell of lymphatic vessel | 3 studies | 26% ± 1% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| lung | 100% | 1218.05 | 578 / 578 | 100% | 16.25 | 1150 / 1155 |
| ovary | 100% | 652.83 | 180 / 180 | 100% | 14.31 | 428 / 430 |
| thymus | 100% | 1126.09 | 653 / 653 | 100% | 17.90 | 602 / 605 |
| skin | 100% | 874.21 | 1805 / 1809 | 100% | 18.43 | 470 / 472 |
| breast | 100% | 1394.60 | 459 / 459 | 99% | 16.05 | 1110 / 1118 |
| prostate | 100% | 746.34 | 244 / 245 | 100% | 17.06 | 500 / 502 |
| uterus | 100% | 1024.04 | 170 / 170 | 99% | 13.66 | 453 / 459 |
| kidney | 100% | 580.43 | 89 / 89 | 98% | 19.37 | 883 / 901 |
| stomach | 99% | 619.72 | 355 / 359 | 98% | 11.96 | 280 / 286 |
| esophagus | 98% | 848.72 | 1413 / 1445 | 99% | 15.68 | 181 / 183 |
| adrenal gland | 99% | 483.34 | 256 / 258 | 97% | 22.42 | 224 / 230 |
| pancreas | 95% | 401.18 | 313 / 328 | 99% | 16.62 | 176 / 178 |
| intestine | 100% | 845.37 | 964 / 966 | 94% | 9.76 | 498 / 527 |
| brain | 93% | 338.70 | 2467 / 2642 | 100% | 14.40 | 705 / 705 |
| bladder | 100% | 970.33 | 21 / 21 | 89% | 10.84 | 449 / 504 |
| liver | 82% | 282.69 | 185 / 226 | 94% | 8.37 | 381 / 406 |
| adipose | 100% | 1679.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 1158.02 | 1335 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 100% | 710.40 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 14.78 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 4.59 | 1 / 1 |
| heart | 100% | 902.54 | 860 / 861 | 0% | 0 | 0 / 0 |
| muscle | 100% | 877.47 | 800 / 803 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 96% | 17.62 | 77 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 93% | 14.14 | 27 / 29 |
| peripheral blood | 60% | 227.65 | 554 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0070374 | Biological process | positive regulation of ERK1 and ERK2 cascade |
| GO_0045821 | Biological process | positive regulation of glycolytic process |
| Gene name | PRXL2C |
| Protein name | Peroxiredoxin-like 2C (AhpC/TSA antioxidant enzyme domain-containing protein 1) (Thioredoxin-like protein AAED1) Peroxiredoxin like 2C |
| Synonyms | C9orf21 AAED1 |
| Description | FUNCTION: May positively regulate ERK1/2 signaling and AKT1 activation leading to HIF1A up-regulation with an increased expression of glycolysis genes and enhanced glycolysis. . |
| Accessions | ENST00000375234.8 H0Y7F1 H0Y5J5 ENST00000411939.5 ENST00000446045.1 Q7RTV5 |